How should I evaluate and manage a patient presenting with hematuria and flushing, including appropriate investigations, treatment (e.g., tranexamic acid), and monitoring?

Evaluation and Management of Hematuria with Flushing

Perform risk-stratified evaluation based on the 2025 AUA/SUFU microhematuria guidelines, with cystoscopy and CT urography for intermediate-to-high risk patients, while tranexamic acid can be used cautiously for gross hematuria but is not routinely indicated for simple microhematuria evaluation. 1

Initial Assessment

History and Physical Examination

Obtain the following specific elements 1:

• Quantify hematuria severity: Document RBC count per high-power field (HPF) on urinalysis—this directly determines risk stratification 1
• Smoking history: Calculate pack-years precisely (≥30 pack-years = high risk) 1
• Age and sex: Men ≥60 years or women ≥60 years have higher malignancy risk 1
• Gross hematuria history: Any prior visible blood significantly elevates risk 1
• Blood pressure measurement: Essential to assess for renal parenchymal disease 1
• Serum creatinine: Evaluate kidney function before imaging decisions 1

Risk Stratification (2025 AUA/SUFU System)

Low/Negligible Risk (0-0.4% malignancy) - ALL criteria must be met 1:

• 3-10 RBC/HPF on single urinalysis
• Women <60 years OR men <40 years
• Never smoker or <10 pack-years

Intermediate Risk (0.2-3.1% malignancy) - ONE or more 1:

• 11-25 RBC/HPF
• Women ≥60 years OR men 40-59 years
• 10-30 pack-years smoking history

High Risk (1.3-6.3% malignancy) - ONE or more 1:

• 25 RBC/HPF

• Men ≥60 years

• 30 pack-years smoking history

Diagnostic Workup

Imaging Selection

For intermediate and high-risk microhematuria 2:

• CT urography (CTU) is the preferred imaging modality—provides comprehensive evaluation of upper tracts and bladder 2
• CTU has 92% sensitivity and 93% specificity for detecting urologic pathology 3

For low-risk microhematuria without risk factors 2:

• Consider observation with repeat urinalysis
• If persistent on three separate urinalyses with ≥5 RBC/HPF, proceed to full evaluation 3

For gross hematuria 2:

• Full urologic workup mandatory regardless of age—30-40% malignancy risk 2
• CT urography plus cystoscopy 2

Cystoscopy Indications

Cystoscopy is essential because most hematuria-associated cancers are bladder cancers, optimally detected by direct visualization 1. Perform cystoscopy for 1, 2:

• All gross hematuria cases
• Intermediate and high-risk microhematuria
• Persistent microhematuria (≥5 RBC/HPF on three urinalyses) even in younger patients 3

Tranexamic Acid Use in Hematuria

When to Consider TXA

Tranexamic acid may be used for gross hematuria requiring continuous bladder irrigation (CBI), but understand its limitations and risks 4, 5.

Intravesical TXA administration 5:

• 1000 mg injected through Foley catheter, clamped for 15 minutes, then start CBI 5
• Reduces ED length of stay (274 vs 411 minutes) and Foley duration (145 vs 308 minutes) 5
• Decreases revisit rates (2.3% vs 12.3%) 5

Critical Safety Warnings

Thromboembolic risk 4:

• Contraindicated in active intravascular clotting 4
• Avoid with pro-thrombotic medications (Factor IX concentrates, hormonal contraceptives) 4
• Venous and arterial thrombosis reported with TXA use 4

Seizure risk 4:

• Can cause focal and generalized seizures 4
• Dose-reduce in renal dysfunction 4
• Monitor closely; discontinue if seizures occur 4

Renal considerations 4, 6:

• Theoretical concern for ureteric clots causing acute renal failure 7
• However, systematic review found no increased renal failure risk in hematuria patients receiving TXA 6
• Dose adjustment required for renal impairment 4

Route verification 4:

• IV use ONLY—never intrathecal 4
• Serious adverse events (seizures, arrhythmias) occur with wrong route 4

TXA Dosing for Hematuria

Standard dosing 5, 7:

• Intravesical: 1000 mg instilled via catheter 5
• Oral: 1000 mg three times daily, then once daily (for polycystic kidney disease with severe hematuria) 7

Renal dose adjustment 4:

• Creatinine 2.83-5.66 mmol/L: 10 mg/kg daily
• Creatinine >5.66 mmol/L: 10 mg/kg every 48 hours or 5 mg/kg every 24 hours

Management Algorithm

1. Confirm true hematuria with microscopic urinalysis (not just dipstick) 1
2. Apply risk stratification using RBC count, age, sex, smoking history 1
3. Low-risk patients: Repeat urinalysis; if persistent ≥5 RBC/HPF on three occasions, proceed to full evaluation 3
4. Intermediate/high-risk or gross hematuria: CT urography AND cystoscopy 1, 2
5. For gross hematuria requiring intervention: Consider intravesical TXA (1000 mg) before CBI to reduce bleeding duration and hospital stay 5
6. Monitor for TXA complications: Assess for thrombosis, seizures, visual changes if prolonged use 4

Key Pitfalls to Avoid

• Do not skip cystoscopy in favor of imaging alone—bladder cancer is the most common malignancy and requires direct visualization 1
• Do not use TXA routinely for simple microhematuria evaluation—it is for active bleeding control, not diagnostic workup 5
• Do not ignore renal function before TXA administration—dose adjustment essential 4
• Do not confuse IV and intrathecal routes for TXA—label syringes clearly 4
• Do not delay evaluation in patients with gross hematuria—34% increased cancer-specific mortality with diagnostic delays 1